Top Markets
#1 龙虾 (Lobster) 龙虾 (Lobster) +64.18%
#2 Cortex Cortex +33.20%
#3 SODAX SODAX +32.87%
#4 DexNet DexNet +23.19%
#5 Akedo Akedo +20.48%
#6 Pons Pons +19.34%
#7 wojak wojak +18.40%
#8 OpenEden OpenEden +16.06%
#9 APEX APEX +13.93%
#10 Official Trump Official Trump +11.37%
Coin of the day
龙虾 (Lobster) 龙虾 (Lobster)
Settings
Language
ENGLISH
Currency
USD
Theme
Biotest AG Biotest AG

Biotest AG

BIO
Rank in Stocks #7308
Biotest AG is a German biopharmaceutical company focused on the global... Biotest AG is a German biopharmaceutical company focused on the global development, manufacturing, and commercialization of biological medications. The firm organizes its activities into the Therapy, Plasma & Services, and Other segments. Its product portfolio addresses critical needs in hematology, clinical immunology, and intensive care medicine. Among its offerings are treatments for hemophilia A (such as Haemoctin and Vihuma) and hemophilia B (like Haemonine), covering both acute care and prevention. Biotest also provides therapies for various viral infections, including cytomegalovirus (Cytotect CP), hepatitis B (Fovepta, Hepatect, Zutectra), and varicella zoster (Varitect). Additionally, its products, such as Intratect and IgG Next Generation, are utilized for primary and secondary immune deficiencies, autoimmune disorders, and certain neurological conditions. The company further supplies solutions to manage circulating blood volume (Albiomin, Biseko), address clotting factor deficiencies (Cofact, Fibrinogen), and combat serious infections like community-acquired pneumonia and COVID-19 (Trimodulin), as well as general bacterial infections (Pentaglobin). Established in 1946 as Biotest Serum-Institut GmbH, the company adopted its current name, Biotest Aktiengesellschaft, in 1986. Headquartered in Dreieich, Germany, Biotest Aktiengesellschaft has been operating as a subsidiary of Grifols, S.A. since January 21, 2022.
Share Price
$47.45
Last synced: 2026-05-13
Market Cap
$1.63B
Change (1 day)
2.04%
Change (1 year)
3.15%
Country
DE
Trade Biotest AG (BIO)

Category

Healthcare
Operating Margin for Biotest AG (BIO)
Operating Margin as of 2026 TTM: 0.00%
According to Biotest AG latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Biotest AG from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.